STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

AICAR (AMPK discourse)

Also known as

AICAR · AICAr · AICA-R · AICA riboside · AICA ribonucleoside · acadesine · 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside · 5-aminoimidazole-4-carboxamide riboside · 5-amino-4-imidazolecarboxamide ribonucleoside · AICA ribonucleotide (endogenous phosphorylated form / nomenclature clash) · ZMP (intracellular AICAR monophosphate / Z-nucleotide) · Z-riboside · CAS 2627-69-2 · exercise-in-a-pill AICAR (media nickname)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Niche talk Systemic SC / IM Metabolic research compounds

Systemic — AICAr/acadesine is a nucleoside converted inside cells to ZMP; not a peptide, local endurance injection or class-wide exposure model.

What people say AICAR endurance and Cardarine-stack talk usually means acadesine/AICAr, a small-molecule nucleoside. Cells convert it to ZMP; neither that metabolite nor other aminoimidazoles can inherit this member's timing. Doses people talk about
Early community IM reports100–150 mcg/day IM

Often discussed with GW 5–10 mg; some were plans, and posters questioned whether AICAR added anything.

Community / vendor low-mg charts1–5 mg/day SC

Secondary charts commonly name 4–6-week blocks. Older 5–10 mg/day SC/IM plans also remain in the full notes.

Historical Phase I exposures10–100 mg/kg oral / IV in Phase I

Healthy-volunteer dose groups, not daily fitness dosing; oral solution bioavailability was below 5%. Other clinical infusion regimens remain separately detailed.

Forum mcg, vendor low-mg and clinical IV exposures stay separate. The full notes retain the much larger animal and allometric figures without turning them into a human ladder.

Half-life & effect duration

Half-life in the body
  • AICAR / acadesine · IVAbout 1.4 hours
  • Older parent-drug summariesAbout 1.5–2 hours
Felt duration people report
  • AICAR accountLittle overall difference during a multi-compound run
  • Single-dose durationNo consistent window reported
Timing context & sources
How it may feel Logs include no obvious effect, subtle cardio readiness, warmth or local irritation. In one heavily stacked account, the poster reported little overall difference and attributed the stimulant-like feel to Helios; AICAR's own contribution was unclear.
Cycles people discuss Community discussion spans 1–2-week tolerance checks, 2–4-week blocks and 4–6 or 6–8-week stack charts. Breaks vary; mouse endurance courses and clinical IV schedules are different contexts, not a validated human washout or fitness cycle. Timing Daily or multi-day patterns come from animal designs and forum habit, not a proven human SC/IM interval. This is discussed as repeated endurance-stack use, not a reliably timed race-day boost; oral solution, IV exposure and intracellular ZMP are different clocks. Stacks Cardarine/GW501516 is the classic co-mention; SR9009, SLU-PP compounds and other metabolic agents also appear. There is no fixed human AICAR-to-GW ratio, and co-use makes cardio effects hard to attribute. Watch for Renal impairment: CLL high-dose IV: renal impairment among notable AEs. MDS/AML Phase I/II at 140–210 mg/kg stopped after 2–3 cycles for serious renal toxicities in comorbid patients. High exposure ≠ gym micro-dose, but renal caution is literature-backed at clinical IV scales.
Related
CardarineSR9009MetforminMOTS-c5-Amino-1MQ

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 1.4 h for IV acadesine parent in the checked healthy-men study.

The separate approximately one-week phase in the 1993 tracer study refers to total plasma radioactivity, not parent acadesine.

Not a half-life for the whole aminoimidazole class, intracellular ZMP, oral products or gray-market SC/IM injections.

  • Dixon et al. — acadesine pharmacokinetics in healthy men (opens in a new tab)Original abstract accessed through Europe PMC core record, PMID 2037706: oral/IV 10, 25, 50 and 100 mg/kg study and post-IV terminal half-life.Healthy men; harmonic-mean terminal parent half-life after IV. Oral bioavailability refers to solution. Not SC/IM gray-market PK, an intracellular ZMP half-life or a class-wide aminoimidazole estimate.
  • Dixon et al. — radiolabeled acadesine disposition (opens in a new tab)Original abstract accessed through Europe PMC core record, PMID 8227467: four men, 15-minute IV 25 mg/kg; plasma total 14C, intact acadesine and RBC ZMP results.The approximately one-week apparent terminal phase belongs to total radioactivity, not parent acadesine. Parent detectability for two hours is not a two-hour half-life.

Felt duration people report

The inspected account does not establish a dependable AICAR-only felt duration.

Odin's Son described little overall difference while using AICAR with GW, Helios and several other agents; the speedy sensation was credited to Helios.

One confounded personal thread, not a controlled time course. Multi-week animal adaptation and parent plasma clearance are not a subjective benefit window.

  • AICAR dosing protocol — personal stack reports (opens in a new tab)Actual Odin's Son comments Sep. 11, 2012 08:45 and Sep. 15, 2012 06:30; opening question separately records plans.AICAR co-used with GW501516, Helios, RIPS and other drugs. Poster credited the speedy/thermogenic sensation to Helios. Replies misidentify AICAR as a peptide and offer unsafe animal scaling; those statements are not adopted as evidence.

What people say 14

  • Community endurance / recovery logs: Sparse forum reports of easier steady cardio, faster between-set readiness, or “elliptical feels free” when stacked with GW — heavily confounded; dose often far below any study HED. forumanecdote
  • Community BP / leaning talk: Occasional logs claim lower BP or leaning when stacked (e.g. with GH water shifts) — not isolated AICAR trial endpoints; treat as anecdote. anecdote
  • Fat-loss / recomp (community): Weak as a solo agent in honest threads; any scale movement usually co-attributed to deficit, cardio volume, and GW/SARM stacks. forum
  • Evidence honesty on benefits: Rodent endurance and metabolic gene data are real and citable; human performance “exercise pill” proof at research-chem doses does not exist; high-dose IV oncology/cardiac exposures are a different risk and endpoint universe. trialforum
  • Mouse endurance (landmark): Narkar et al. Cell 2008 — sedentary C57Bl/6J mice given AICAR ~500 mg/kg/day IP for ~4 weeks ran ~44% farther and ~23% longer on treadmill tests; AMPK/ACC phosphorylation and oxidative gene programs up (UCP3 etc.). animal
  • Mouse + PPARδ synergy: Same line — GW1516 alone needed exercise for full endurance synergy; AICAR alone reprogrammed muscle; short gene-signature work used AICAR ~250 mg/kg/day IP ± GW ~5 mg/kg/day oral for ~6 days. Stack lore (“AICAR + cardarine”) traces here. animal
  • Oxidative fiber / metabolic genes: AICAR induced fatigue-resistant / oxidative-type gene programs and mitochondrial biogenesis–adjacent signatures in rodent muscle without requiring training stimuli in the landmark design. animal
  • Fat oxidation / fuel shift (preclinical): Animal and cell work links AMPK activation to increased fatty-acid oxidation, reduced anabolic lipid synthesis in liver, and metabolic reprogramming under energy stress. animallab
  • Glucose uptake (muscle, AMPK-dependent in KO models): Multiple AMPKα2 / α3 knockout and kinase-dead mouse lines abolish or blunt AICAR-stimulated skeletal-muscle glucose uptake; treadmill + AICAR insulin-sensitizing stories also AMPK-linked in several designs. animal
  • Human IV metabolic signals: Healthy-volunteer work (e.g. ~10 mg/kg/h IV × 3 h) acutely stimulated muscle 2-DG uptake with only minor whole-body glucose-disposal change; systemic AICAR can lower hepatic glucose output in older metabolic studies. trial
  • Hypoglycemia risk signal (preclinical/clinical adjacency): Acute AMPK-dependent hypoglycemia described in transgenic models; mild asymptomatic hypoglycemia noted in some older angina/ischemia dose-ranging work. Not a “fat burner buzz.” animaltrial
  • Cardiac development history: 1990s–2000s CABG / ischemia trials of continuous IV acadesine (often ~0.1 mg/kg/min × ~7 h, ~42 mg/kg total, sometimes with cardioplegia additives). Early meta-analyses suggested reduced early cardiac death/MI; later RED-CABG Phase III did not meet composite morbidity/mortality endpoints. Different goal than gym endurance. trial
  • CLL antileukemic activity (high IV): Phase I/II relapsed/refractory CLL — single IV doses 50–315 mg/kg; 210 mg/kg called MTD/OBD with acceptable multi-dose safety profile in that oncology context; activity reported in poor-prognosis patients. trial
  • Cognition / motor (aged mice): Secondary AMPK-agonist work reports 500 mg/kg AICAR benefits on cognition/motor coordination in young and old mice that depended on muscle AMPKα2 — not a human nootropic claim. animal

Doses people talk about 21

  • Allometric / HED chaos: Naive mg/kg scaling of 500 mg/kg mouse → multi-gram human daily talk on forums (e.g. ~3 g/day lore for ~200 lb users in older board posts). Formal HED discussions in recent review responses have floated ~42 mg/kg-order figures for a 60 kg person as rough allometry — still not a validated athletic dose. Cost and logistics kill true study-scale human mimics. forumtrial
  • Community / vendor injectable charts (research-chem): Frequently cited band ~10–50 mg/kg SC or IM — pure extrapolation from animal ranges, not human PK-guided fitness dosing. For a 80 kg person that is hundreds of mg to multi-gram territory per day — rarely what people actually buy or run. forum
  • Community micro-dose forum history (early 2010s): Professional Muscle–class logs discussed ~100–150 mcg/day IM (sometimes planned starts at 100 mcg) stacked with GW 5–10 mg — orders of magnitude below study exposures; posters themselves questioned whether AICAR contributed vs GW alone. forumanecdote
  • Community low-mg daily charts (secondary vendor/blog culture): Some modern “peptide guide” pages list ~1–5 mg daily SC, 50 mg vials, 4–6 week cycles — still far below mouse HED and unvalidated. forum
  • Community mid-mg talk: Occasional 5–10 mg/day SC/IM plans appear in older stack planning posts (e.g. “start 5 → 10 mg”); still not trial-grade and still confounded when GW co-runs. forum
  • Route hierarchy for seriousness: Published mouse = IP (sometimes SC/oral); published human = continuous IV; community experimental = SC/IM of research powder/vials; oral capsules/powders = high uncertainty given <5% oral F. trialforum
  • Uncertainty stack: Labeled mg ≠ delivered active; hydration/uric acid; SC vs IV exposure; fake “peptide AICAR”; and mcg-vs-mg unit errors all break dose interpretation. forum
  • Oral retail products: Sold despite known poor oral bioavailability; hard to map labeled mg to systemic exposure; identity/potency still untested. forumtrial
  • Framing: All figures below are historical trial exposures, animal regimens, or community/vendor discussion — research and education only. Not medical advice, not a protocol, not consumption guidance. Identity and purity of gray-market material are unverified. forumtrial
  • Tolerability ceiling language in reviews: Summaries state humans tolerated up to ~210 mg/kg IV in oncology settings with defined AE profiles; “tolerated in trial” ≠ safe research-chem self-experimentation. trial
  • Mouse endurance (Narkar primary): ~500 mg/kg/day intraperitoneal for ~4 weeks (sedentary endurance arm). animal
  • Mouse gene-combo arm: ~250 mg/kg/day IP AICAR ± GW1516 ~5 mg/kg/day oral for ~6 days in short signature work. animal
  • Mouse other common bands: Literature spans roughly low tens of mg/kg up through 250–500 mg/kg (and some models higher) by route (IP/SC/oral) and endpoint (metabolic, cancer, cognition). Example clusters: ~50 mg/kg, ~150 mg/kg/day multi-week, ~0.5 mg/g (500 mg/kg) SC daily × 14 days in some muscle designs. animal
  • Oral mouse note: Some cachexia/endurance-adjacent write-ups describe 500 mg/kg/day oral multi-week regimens; oral F and first-pass still limit mapping to humans. animal
  • Human oral bioavailability: Phase I healthy volunteers (Dixon et al. 1991 lineage) — PO and IV 10, 25, 50, 100 mg/kg; drug poorly bioavailable orally (<5% in solution). Lesch-Nyhan oral case (30→100 mg/kg/day) showed no plasma rise, consistent with <5% oral F. trial
  • Human IV — Phase I / early cardiac ranging: Single or short IV exposures from ~6–48 mg/kg up through 50–100 mg/kg in various 1990s designs; mild transient sides at lower bands. trial
  • Human IV — CABG / ischemia “classic” regimen: Continuous IV ~0.1 mg/kg/min for ~7 hours (≈42 mg/kg total), sometimes with acadesine in cardioplegia/prime (~5 µg/mL class additives in protocols). Alternate early arms used ~0.05–0.38 mg/kg/min class rates. trial
  • Human IV — metabolic physiology: Continuous IV ~10 mg/kg/h for 3 hours in healthy volunteers (muscle glucose-uptake study). Intra-arterial forearm infusion studies used mg/min/dL tissue rates for vascular endpoints. trial
  • Human IV — CLL Phase I/II: Single 4-h infusions starting 50 mg/kg escalating to 315 mg/kg; multi-dose work at 210 mg/kg (MTD/OBD). trial
  • Human IV — MDS/AML refractory: 140 or 210 mg/kg continuous IV class exposures; trial stopped after few cycles for serious renal toxicities in comorbid patients. trial
  • Timing: Animal multi-day designs were usually once daily or study-defined. Human IV parent PK describes plasma decline, not a long depot; daily research-chem talk remains a habit, not a measured SC/IM steady-state schedule or an interval established by the IV half-life. animaltrial

How it may feel 8

  • Day 1 / first SC–IM doses: Existing logs describe little or no stimulant kick, with occasional warmth, injection awareness or subtle “cardio readiness.” In the inspected 2012 thread, Odin's Son described little overall difference on a multi-drug stack and credited the speedy/thermogenic feel to Helios, not AICAR alone. forumanecdote
  • Days 1–3: Tolerance/site comfort and uric-acid / hydration awareness dominate practical talk more than dramatic performance jumps. forum
  • Days 4–7: Still often flat subjectively; early “easier LISS” notes appear in a minority of stacked logs. forumanecdote
  • Weeks 1–2: Common first honest checkpoint for “anything on steady cardio?” Mouse endurance remodeling was multi-week continuous dosing — not a one-shot feel. animalforum
  • Weeks 2–4: Modal keep/drop window for research-chem runs; also aligns with ~4-week Narkar protocol length people try (poorly) to imitate. animalforum
  • Weeks 4–8: Longer endurance-stack blocks when co-run with cardarine; attribution to AICAR alone remains weak. forum
  • No change by ~2–3 weeks: Threads blame (in rough order) underdosing vs mouse HED, oral dead product, fake identity, short coverage/half-life, or “AICAR is placebo at forum mcg doses.” forum
  • Hours 0–6 (IV historical context): Clinical infusions ran multi-hour continuous IV; parent plasma falls rapidly after stop (hours-scale). Community injects are not that regimen. trial

Cycles people discuss 9

  • Community short probe: 1–2 weeks for injection tolerance, subjective cardio feel, and early side watch (uric acid, site, malaise). forum
  • Community endurance / stack blocks: 2–4 weeks commonly named; 4–6 week charts appear on secondary vendor blogs; some extend with GW-length cuts toward 6–8 weeks. Long-term research-chem safety not established. forum
  • Time off: Inconsistent; seasonal re-use or equal-time-off heuristics appear without a pharmacology-backed washout standard for gray-market use. forum
  • Not PCT: No classic SERM/AI hormone PCT framed for AICAR alone; PCT talk only appears when stacked with suppressive SARMs/AAS. forum
  • Bloodwork culture (risk-aware talk): Uric acid, renal panel, CBC (historical anemia/thrombocytopenia signals at high IV), and glucose sometimes mentioned — not a validated community monitoring standard. trialforum
  • Mouse endurance protocol length: ~4 weeks continuous daily AICAR in the Narkar sedentary-endurance design. animal
  • Mouse short combo / signature windows: ~6 days for dual-agent gene work; multi-week (e.g. 2–5+ weeks) for metabolic/obesity/disease models depending on lab. animal
  • Clinical multi-dose (CLL): Limited multi-infusion schedules at OBD (e.g. two or five doses at 210 mg/kg in protocol language) — oncology context only. trial
  • Continuous open-ended use: Not supported by a chronic oral human safety database; cardiac programs were acute perioperative infusions, not months-long gym cycles. trial

Timing 8

  • Multiphase / assay notes: Secondary summaries mention longer terminal phases in the tens-of-hours range; those require their own study, population and analyte context. Separately, Dixon et al. (1993) found an apparent terminal phase of about one week for total plasma 14C after IV radiolabeled acadesine—not parent drug. Intact acadesine was measurable for only 2 h after infusion, which is detectability, not a 2 h half-life. Neither establishes a weekly depot or once-weekly research-chem schedule. trialforum
  • Downstream adaptations: AMPK/transcriptional and training adaptations may outlast one dose window in principle; users still report subjective edges fading after stop when training continuity is the real residual. forumanecdote
  • Human gray-market SC/IM PK gap: No formal public PK package for research-chem subcutaneous self-administration schedules used on forums. forumtrial
  • IV plasma half-life (parent): Older summaries use roughly 1.5–2 h, but Dixon et al. (1991) reported a harmonic-mean terminal t½ of 1.4 h for acadesine/AICAr after IV administration in healthy men. The oral/IV study tested 10, 25, 50 and 100 mg/kg; this is not gray-market SC/IM kinetics. trial
  • Oral coverage: Poor oral F (<5%) means oral timing habits do not map cleanly to IV or animal IP exposure. trial
  • Intracellular ZMP logic: Active AMP-mimetic species is intracellular ZMP after phosphorylation — tissue “coverage” is not the same as plasma parent half-life. triallab
  • Schedules versus PK: Animal endurance/gene-remodeling designs used daily or multi-day continuous dosing for weeks rather than isolated “race day only” exposure. That study design does not follow automatically from the short IV parent-plasma half-life and does not validate a human SC/IM interval. animaltrial
  • Anti-doping detection angle: WADA-funded work notes AICAR enters erythrocytes and forms AICAR ribotide as a longer-term RBC marker concept; in-vitro incubations used hundreds–thousands ng/mL plasma-simulating levels aligned with clinical literature. Detection science ≠ efficacy. trial

More on what it is 9

  • Naming trap: Literature mixes AICAr (riboside, the research/clinical molecule), AICAR (often used loosely for the same compound), and ZMP / AICA ribotide (the intracellular monophosphate that actually binds AMPK’s γ subunit). Forum “AICAR peptide” labels are category errors. trialforum
  • Why people care: 2008 Narkar/Evans Cell “exercise mimetic” mouse paper (sedentary mice + AICAR ran ~44% farther) + classic GW501516 stack lore + early Tour de France / cycling supply-network doping headlines → gray-market endurance chem culture. animalforum
  • Layers not to confuse: Mouse 250–500 mg/kg IP daily ≠ multi-hour cardiac IV at 0.1 mg/kg/min (~42 mg/kg total) ≠ forum mcg/day IM logs ≠ vendor “10–50 mg/kg SC” charts. Same molecule name, wildly different exposures. animaltrialforum
  • What it is: Synthetic small-molecule nucleoside (acadesine / AICAr; CAS 2627-69-2) — an exogenous dephosphorylated AICA riboside. Not a peptide, not a SARM, not a stimulant. trial
  • Mechanism (plain): Enters cells → adenosine kinase phosphorylates it to ZMP → ZMP mimics AMP → allosteric AMPK activation (and helps Thr172 phosphorylation stability). ZMP is ~40–50× less potent than AMP, so high intracellular accumulation is typical — which also drives off-target AMP-sensitive enzyme effects. triallab
  • AMPK-independent reality: Reviews (e.g. Višnjić et al. Cells 2021) stress many AICAr effects are AMPK-independent (gluconeogenesis, OXPHOS, nucleotide/pyrimidine disruption, some antiproliferative actions). “It activated AMPK on a blot” ≠ every claimed benefit is AMPK-mediated. trial
  • Clinical history (different use case): Acadesine was developed as an adenosine-regulating agent for CABG / ischemia (Phase II–III IV infusions), later explored in CLL and MDS/AML at much higher IV mg/kg — not as a gym endurance drug. RED-CABG failed to confirm hard outcomes; hematology high-dose work hit renal and other toxicities. trial
  • Evidence honesty: Strong rodent AMPK/endurance/metabolic package + older human IV cardiac/metabolic/CLL PK-safety data; no modern athletic RCTs proving gray-market SC/oral “cycles” work. Oral bioavailability in humans is poor (<5%). trial
  • Status: Not FDA-approved for endurance, fat loss, or metabolic disease as a chronic oral med. WADA prohibits AMPK activators including AICAR at all times (S4 hormone/metabolic modulators; banned ~2009). USADA notes no TUE pathway because it is not an approved medicine. trial

Stacks 10

  • AICAR + GW501516 (cardarine) — classic dual exercise-mimetic pair: Directly inspired by Narkar AMPK + PPARδ mouse work. Community GW often ~5–20 mg oral/day (modal ~10 mg) while AICAR dose in the same logs swings from mcg-class IM to vendor mg/kg charts — dual attribution is the norm and GW alone can explain much of the cardio feel. animalforum
  • Stack ratio honesty: There is no fixed human “mg AICAR : mg GW” clinical ratio. Mouse short-combo work used ~250 mg/kg IP AICAR with ~5 mg/kg oral GW — not a capsule recipe. Vendor pre-mixes (if any) vary and are unregulated. animalforum
  • AICAR + SR9009 (Stenabolic): Named in broader “endurance / metabolic” shopping lists; SR9009 brings its own short-half-life split-dosing lore and oral-F fights — triple confound with training. forum
  • AICAR + SLU-PP-332 / SLU-PP-class: Comparison and occasional co-mention as next-gen exercise-mimetic peers (ERR vs AMPK axes); no head-to-head human trial. forum
  • AICAR vs metformin (informal AMPK talk): Both discussed as AMPK-adjacent metabolic tools; exposures, oral practicality, and evidence bases are completely different — not interchangeable protocols. trialforum
  • AICAR + MOTS-c / mitochondrial peptides / NAD-axis stacks: Biohack adjacency for “mito + AMPK” narratives; evidence remains siloed preclinical + anecdote. forum
  • AICAR + SARM cut stacks (Ostarine etc.): Occasional recomp templates where GW/AICAR cover cardio/fat-ox talk and a SARM covers soft muscle retention — suppression/lipid risk tracks the SARM. forum
  • Real base still wins honest logs: Progressive cardio + diet are what careful writers credit first; compounds are add-ons with confounded credit. forum
  • Anti-doping stack risk: Multi-agent metabolic stacks (AICAR + GW ± others) raise detection and sanction risk for tested athletes; both AICAR and GW501516 are prohibited. trial
  • Oncology methotrexate adjacency (lab only): Methotrexate can potentiate ZMP accumulation from exogenous AICAr in experimental cancer/metabolic models — not a bodybuilding stack; listed only so researchers do not confuse lab potentiation with gym advice. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 14

  • Injection-site reactions (community): Redness, sting, local irritation with research injectables. forum
  • GI / malaise / fatigue (community): Nausea, fatigue, nonspecific unwell feelings in minority logs — often stacked and confounded. forumanecdote
  • Source / identity risk: Mislabel as “peptide,” wrong dose units (mcg vs mg), underdosed vials, degraded powder, or different molecule entirely. Null results and adverse events both hard to interpret without assay. forum
  • Oral product trap: Marketing oral AICAR despite documented <5% human oral bioavailability — exposure may be negligible even if label mg looks large. trialforum
  • Not risk-free just because “mouse endurance was cool”: Perioperative cardiac programs and oncology MTD work define real human AE profiles at IV scale; gray-market chronic SC use has no equivalent safety database. trialforum
  • Renal impairment: CLL high-dose IV: renal impairment among notable AEs. MDS/AML Phase I/II at 140–210 mg/kg stopped after 2–3 cycles for serious renal toxicities in comorbid patients. High exposure ≠ gym micro-dose, but renal caution is literature-backed at clinical IV scales. trial
  • Infusion-related hypotension: Transient, clinically significant infusion-related hypotension reported in CLL high-dose IV work. trial
  • Hematologic transients: Transient anemia and/or thrombocytopenia (often framed not clinically significant at OBD) in CLL multi-dose experience. trial
  • Hyperlactacidemia / metabolic labs: Older CAD dose-ranging noted hyperlactacidemia at higher IV doses; mild asymptomatic hypoglycemia appears in some ischemia-era reports. trial
  • Mild / transient Phase I sides: Healthy-volunteer PO/IV ranging (10–100 mg/kg) generally “well tolerated” with only mild transient effects in classic summaries — still not a green light for unmonitored self-use. trial
  • AMPK “wrong tissue / overdrive” theoretical risks: USADA and related education pieces warn that excessive or mistimed AMPK activation can, in principle, contribute to serious biology (including neurodegeneration or impaired cell division narratives in review-level caution). Accumulation of endogenous AICAR is also linked to metabolic disorders in humans (e.g. purine-pathway disease context). trial
  • AMPK-independent cytotoxicity / cell-cycle effects: Lab literature shows S-phase arrest, pyrimidine starvation, and antiproliferative actions in cancer lines — reminder this is a bioactive metabolic disruptor, not a benign endurance vitamin. triallab
  • Hyperuricemia (most predictable clinical AE): AICAR metabolism feeds uric acid. Cardiac-surgery-era trials documented asymptomatic uric-acid rises (secondary summaries often ~1.6 mg/dL class) sometimes managed with allopurinol in protocols. Gout-prone individuals are the practical risk framing. High-dose CLL work also listed grade ≥2 hyperuricemia (often called not clinically significant in that write-up). trial
  • WADA / tested athletes: AICAR and AMPK activators prohibited at all times; no TUE because not an approved therapeutic. RBC-marker research exists for long-term detection concepts. Research-only framing ≠ legal sport use. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →